Literature DB >> 34416110

Selective Neutral pH Inhibitor of Cathepsin B Designed Based on Cleavage Preferences at Cytosolic and Lysosomal pH Conditions.

Michael C Yoon1,2, Angelo Solania3, Zhenze Jiang1, Mitchell P Christy4, Sonia Podvin1, Charles Mosier1, Christopher B Lietz1, Gen Ito1, William H Gerwick4, Dennis W Wolan3, Gregory Hook5, Anthony J O'Donoghue1, Vivian Hook1,6.   

Abstract

Cathepsin B is a cysteine protease that normally functions within acidic lysosomes for protein degradation, but in numerous human diseases, cathepsin B translocates to the cytosol having neutral pH where the enzyme activates inflammation and cell death. Cathepsin B is active at both the neutral pH 7.2 of the cytosol and the acidic pH 4.6 within lysosomes. We evaluated the hypothesis that cathepsin B may possess pH-dependent cleavage preferences that can be utilized for design of a selective neutral pH inhibitor by (1) analysis of differential cathepsin B cleavage profiles at neutral pH compared to acidic pH using multiplex substrate profiling by mass spectrometry (MSP-MS), (2) design of pH-selective peptide-7-amino-4-methylcoumarin (AMC) substrates, and (3) design and validation of Z-Arg-Lys-acyloxymethyl ketone (AOMK) as a selective neutral pH inhibitor. Cathepsin B displayed preferences for cleaving peptides with Arg in the P2 position at pH 7.2 and Glu in the P2 position at pH 4.6, represented by its primary dipeptidyl carboxypeptidase and modest endopeptidase activity. These properties led to design of the substrate Z-Arg-Lys-AMC having neutral pH selectivity, and its modification with the AOMK warhead to result in the inhibitor Z-Arg-Lys-AOMK. This irreversible inhibitor displays nanomolar potency with 100-fold selectivity for inhibition of cathepsin B at pH 7.2 compared to pH 4.6, shows specificity for cathepsin B over other cysteine cathepsins, and is cell permeable and inhibits intracellular cathepsin B. These findings demonstrate that cathepsin B possesses pH-dependent cleavage properties that can lead to development of a potent, neutral pH inhibitor of this enzyme.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34416110      PMCID: PMC9104225          DOI: 10.1021/acschembio.1c00138

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   4.634


  89 in total

1.  The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release.

Authors:  Tobias Hoegen; Nadin Tremel; Matthias Klein; Barbara Angele; Hermann Wagner; Carsten Kirschning; Hans-Walter Pfister; Adriano Fontana; Sven Hammerschmidt; Uwe Koedel
Journal:  J Immunol       Date:  2011-10-14       Impact factor: 5.422

2.  Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery.

Authors:  Santiago Vilar; Giorgio Cozza; Stefano Moro
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

3.  Extracellular presence of the lysosomal proteinase cathepsin B in rheumatoid synovium and its activity at neutral pH.

Authors:  J S Mort; A D Recklies; A R Poole
Journal:  Arthritis Rheum       Date:  1984-05

4.  Destructin-1 is a collagen-degrading endopeptidase secreted by Pseudogymnoascus destructans, the causative agent of white-nose syndrome.

Authors:  Anthony J O'Donoghue; Giselle M Knudsen; Chapman Beekman; Jenna A Perry; Alexander D Johnson; Joseph L DeRisi; Charles S Craik; Richard J Bennett
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-05       Impact factor: 11.205

5.  Increased intracranial pressure after diffuse traumatic brain injury exacerbates neuronal somatic membrane poration but not axonal injury: evidence for primary intracranial pressure-induced neuronal perturbation.

Authors:  Audrey D Lafrenaye; Melissa J McGinn; John T Povlishock
Journal:  J Cereb Blood Flow Metab       Date:  2012-07-11       Impact factor: 6.200

6.  Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation.

Authors:  P C Almeida; I L Nantes; J R Chagas; C C Rizzi; A Faljoni-Alario; E Carmona; L Juliano; H B Nader; I L Tersariol
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

7.  Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Aβ pathology at the lysosome.

Authors:  Line De Kimpe; Elise S van Haastert; Archontia Kaminari; Rob Zwart; Helma Rutjes; Jeroen J M Hoozemans; Wiep Scheper
Journal:  Age (Dordr)       Date:  2012-04-04

Review 8.  Cysteine cathepsins: from structure, function and regulation to new frontiers.

Authors:  Vito Turk; Veronika Stoka; Olga Vasiljeva; Miha Renko; Tao Sun; Boris Turk; Dušan Turk
Journal:  Biochim Biophys Acta       Date:  2011-10-12

Review 9.  Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging.

Authors:  Hiroshi Nakanishi
Journal:  Neural Regen Res       Date:  2020-01       Impact factor: 5.135

10.  The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity.

Authors:  D Musil; D Zucic; D Turk; R A Engh; I Mayr; R Huber; T Popovic; V Turk; T Towatari; N Katunuma
Journal:  EMBO J       Date:  1991-09       Impact factor: 11.598

View more
  8 in total

Review 1.  Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders.

Authors:  Gregory Hook; Thomas Reinheckel; Junjun Ni; Zhou Wu; Mark Kindy; Christoph Peters; Vivian Hook
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

2.  Dysregulation of Neuropeptide and Tau Peptide Signatures in Human Alzheimer's Disease Brain.

Authors:  Sonia Podvin; Zhenze Jiang; Ben Boyarko; Leigh-Ana Rossitto; Anthony O'Donoghue; Robert A Rissman; Vivian Hook
Journal:  ACS Chem Neurosci       Date:  2022-06-27       Impact factor: 5.780

3.  Cathepsin B Relocalization in Late Membrane Disrupted Neurons Following Diffuse Brain Injury in Rats.

Authors:  Martina L Hernandez; Michael Marone; Karen M Gorse; Audrey D Lafrenaye
Journal:  ASN Neuro       Date:  2022 Jan-Dec       Impact factor: 5.200

4.  Molecular Features of CA-074 pH-Dependent Inhibition of Cathepsin B.

Authors:  Michael C Yoon; Mitchell P Christy; Von V Phan; William H Gerwick; Gregory Hook; Anthony J O'Donoghue; Vivian Hook
Journal:  Biochemistry       Date:  2022-02-04       Impact factor: 3.321

Review 5.  Low-level lysosomal membrane permeabilization for limited release and sublethal functions of cathepsin proteases in the cytosol and nucleus.

Authors:  Thomas Reinheckel; Martina Tholen
Journal:  FEBS Open Bio       Date:  2022-03-09       Impact factor: 2.693

6.  Discovery of pH-Selective Marine and Plant Natural Product Inhibitors of Cathepsin B Revealed by Screening at Acidic and Neutral pH Conditions.

Authors:  Von V Phan; Charles Mosier; Michael C Yoon; Evgenia Glukhov; Conor R Caffrey; Anthony J O'Donoghue; William H Gerwick; Vivian Hook
Journal:  ACS Omega       Date:  2022-07-12

7.  Cathepsin B Dipeptidyl Carboxypeptidase and Endopeptidase Activities Demonstrated across a Broad pH Range.

Authors:  Michael C Yoon; Vivian Hook; Anthony J O'Donoghue
Journal:  Biochemistry       Date:  2022-08-18       Impact factor: 3.321

Review 8.  Extralysosomal cathepsin B in central nervous system: Mechanisms and therapeutic implications.

Authors:  Junjun Ni; Fei Lan; Yan Xu; Hiroshi Nakanishi; Xue Li
Journal:  Brain Pathol       Date:  2022-04-12       Impact factor: 7.611

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.